Arch Biopartners Inc (OP: ACHFF )

1.090 USD +0.001 (+0.07%)

Streaming Delayed Price Updated: 10:34 AM EDT, Apr 13, 2021 Add to My Watchlist

Price and Volume

Volume	1,000
Open	1.090
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	1.089
Today's Range	1.090 - 1.090
52wk Range	0.6213 - 1.320
Shares Outstanding	58,457,929
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Turkish Ministry of Health Approves Increase in Patient Recruitment into the Phase II Trial for LSALT Peptide

March 30, 2021

Arch Biopartners Enters Exclusive License Agreement with the University of Cincinnati for AB569 Topical Wound Treatment

March 24, 2021

Performance

YTD	-4.39%	-4.39%
1 Month	+8.95%	+8.95%
3 Month	+1.87%	+1.87%
6 Month	-7.63%	-7.63%
1 Year	+65.40%	+65.40%

More News

Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide

March 16, 2021

ARCH Scientist Publishes Paper Showing Pre-Clinical Efficacy of AB569 in Eradicating Multi-Drug Resistant Pathogens Acinetobacter baumannii and Acinetobacter spp

March 04, 2021

Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

February 26, 2021

Arch Biopartners Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase II Trial for LSALT Peptide

February 02, 2021

University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

January 05, 2021

Arch Biopartners Receives Government of Canada Funding to Support Phase II Therapeutic Trial of Metablok for COVID-19

December 15, 2020

VA San Diego Healthcare System Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

December 10, 2020

Arch Biopartners Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19

November 05, 2020

First Patient Dosed in Phase II Trial to Treat Complications in COVID-19

October 16, 2020

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Chronicle Journal: Finance

Chronicle Journal

Arch Biopartners Inc (OP: ACHFF )

Price and Volume

Top News

Performance

More News

Contact us

Sections

Services

Search